Head-to-head evidence
Abemaciclib vs Ribociclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
Abemaciclib · Verzenio
Marketed by Eli Lilly
NCT02102490 · Phase 2 · completed
This was a single-arm, open-label study of 132 participants with no placebo or active comparator and no randomization or blinding. Its primary endpoint was the clinical tumor-response rate, reported as 19.7%, but the uncontrolled design makes the result descriptive rather than comparative evidence.
Next expected readout: December 2026 · NCT05307705 (registry estimate)
Ribociclib
Marketed by Novartis
NCT02422615 · Phase 3 · completed
The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.
Next expected readout: November 2026 · NCT02608216 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abemaciclib's landscape · Ribociclib's landscape